Catalog No.: PC-49557Not For Human Use, Lab Use Only.
FR054 (FR-054) is a specific small molecule inhibitor of hexosamine biosynthetic pathway (HBP) enzyme N-Acetylglucosamine-phosphate Mutase (PGM3), shows a remarkable anti-breast cancer effect.
FR054 (FR-054) is a specific small molecule inhibitor of hexosamine biosynthetic pathway (HBP) enzyme N-Acetylglucosamine-phosphate Mutase (PGM3), shows a remarkable anti-breast cancer effect.
FR054 enhanced the stability of PGM3 protein in a dose-dependent manner and with a more potent binding than the natural substrate GlcNAc-6-P.
FR054 induced an early proliferation arrest followed by a marked cell death increase in breast cancer cells.
FR054 (250 μM, 24 h) treatment efficiently affected both N- and O-glycosylation levels in MDA-MB-231 cells.
FR054 reduced MDA-MB-231 cell adhesion, migration, and integrin β1 membrane localization, induced ER stress and a ROS-dependent apoptotic cell death.
FR054 (1000 mg/kg, 10% DMSO) administered in single dose reduced tumor growth in nude mice xenograft model of TNBC cells MDA-MB-231.
